ETX-880 is an experimental small molecule from Ensem Therapeutics, in preclinical development for MSI-high colorectal cancer, MSI-high gastric cancer and MSI-high endometrial cancer.
ETX-880 is a small molecule (oral, covalent) from Ensem Therapeutics. An oral, selective covalent inhibitor of Werner helicase (WRN), being developed for microsatellite instability-high cancers. Its furthest stage is preclinical development, for MSI-high colorectal cancer, MSI-high gastric cancer and MSI-high endometrial cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline page describes only in vitro and xenograft data; no ClinicalTrials.gov record for ETX-880. It has not been shown to work in people.
An oral, selective covalent inhibitor of Werner helicase (WRN), being developed for microsatellite instability-high cancers. Connects to WRN helicase (MSI-high cancers).
1.ETX-880 slips into a pocket on WRN helicase (MSI-high cancers).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ETX-880" OR ABSTRACT:"ETX-880") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ETX-880, not a curated reading list.
Shares Ensem Therapeutics and the tag pipeline.
Shares Ensem Therapeutics and the tag pipeline.
Shares Ensem Therapeutics and the tag pipeline.
Shares Ensem Therapeutics and the tag pipeline.
Shares WRN helicase (MSI-high cancers) and the tag pipeline.
Shares Ensem Therapeutics and the tag pipeline.
Shares WRN helicase (MSI-high cancers) and the tag pipeline.
Shares WRN helicase (MSI-high cancers) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/